Development of Mirror-Image VHHs with Less Immunogenicity



de

Éditeur :

Springer


Paru le : 2025-01-13



eBook Téléchargement , DRM LCP 🛈 DRM Adobe 🛈
Lecture en ligne (streaming)
200,44

Téléchargement immédiat
Dès validation de votre commande
Ajouter à ma liste d'envies
Image Louise Reader présentation

Louise Reader

Lisez ce titre sur l'application Louise Reader.

Description

This book outlines the chemical synthesis of therapeutic targets and a screening process for unexplored mirror-image single-domain antibodies (D-VHH).
This book first describes the chemical synthesis of model VHH and the characteristics of both enantiomeric VHHs, including binding activity, biodistribution and immunogenicity. Immunogenicity testing in mice demonstrated that administration of conventional L-VHH induced the generation of anti-drug antibodies while D-VHH-binding antibodies were not observed in D-VHH-immunized mice. Second, it is explained that the T7-phage-based mirror-image screening system was developed to identify D-VHH antibody fragments capable of binding to vascular endothelial growth factors. Additionally, this book details the chemical synthesis of full-length hepatitis B virus core protein and interleukin-6 for the application of exploring D-VHHs and other mirror-image molecules.
Demonstrating that it is possible to develop a D-VHH that preferentially binds the native target protein and exhibits reduced immunogenicity, this book is useful for anyone interested in developing alternative biotherapeutics with reduced immunogenicity by combining chemical and biological approaches.
Pages
116 pages
Collection
n.c
Parution
2025-01-13
Marque
Springer
EAN papier
9789819613007
EAN PDF
9789819613014

Informations sur l'ebook
Nombre pages copiables
1
Nombre pages imprimables
11
Taille du fichier
10220 Ko
Prix
200,44 €
EAN EPUB
9789819613014

Informations sur l'ebook
Nombre pages copiables
1
Nombre pages imprimables
11
Taille du fichier
15360 Ko
Prix
200,44 €

Keisuke Aoki received a PhD degree in Pharmaceutical Sciences from Kyoto University supervised by Prof. Hiroaki Ohno and Prof. Shinya Oishi in 2024. He currently works for Ono Pharmaceutical Co., Ltd.

Suggestions personnalisées